Boston Scientific Corporation (BSX)
Stock Price Chart
Key Info
| Market Cap | 56.24B |
| Revenue (ttm) | 10.16B |
| Net Income (ttm) | 3.99B |
| Shares Out | 1.43B |
| EPS (ttm) | 2.83 |
| PE Ratio | 13.89 |
| Forward PE | 36.50 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $39.31 |
| Previous Close | $38.98 |
| Change ($) | 0.33 |
| Change (%) | 0.85% |
| Day's Open | 39.46 |
| Day's Range | 39.25 - 39.87 |
| Day's Volume | 7,951,489 |
| 52-Week Range | 24.10 - 46.62 |
More Stats
| Market Cap | 56.24B |
| Enterprise Value | 64.05B |
| Earnings Date (est) | Oct 21, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 1.43B |
| Float | 1.43B |
| EPS (basic) | 2.86 |
| EPS (diluted) | 2.83 |
| FCF / Share | 0.72 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 7.20% |
| FCF Yield | 1.81% |
| Payout Ratio | n/a |
| Shares Short | 14.89M |
| Short Ratio | 1.25 |
| Short % of Float | 1.04% |
| Beta | 0.95 |
| PE Ratio | 13.89 |
| Forward PE | 36.50 |
| P/FCF Ratio | 55.30 |
| PS Ratio | 5.54 |
| PB Ratio | 3.47 |
| Revenue | 10.16B |
| Operating Income | 669.00M |
| Net Income | 3.99B |
| Free Cash Flow | 1.02B |
| Net Cash | -7.81B |
| Net Cash / Share | -5.46 |
| Gross Margin | 75.14% |
| Operating Margin | 6.59% |
| Profit Margin | 39.20% |
| FCF Margin | 10.01% |
| ROA | 2.57% |
| ROE | 31.83% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10,735 | 9,823 | 9,048 | 8,386 | 7,477 | 7,380 | 7,143 | 7,249 | 7,622 | 7,806 |
| Revenue Growth | 9.28% | 8.57% | 7.89% | 12.16% | 1.31% | 3.32% | -1.46% | -4.89% | -2.36% | - |
| Gross Profit | 7,619 | 7,010 | 6,455 | 5,962 | 5,304 | 5,170 | 4,969 | 4,900 | 4,963 | 5,207 |
| Operating Income | 1,517 | 1,506 | 1,285 | 447 | -283 | -313 | 82.00 | -3,883 | 126 | -656 |
| Net Income | 4,700 | 1,671 | 104 | 347 | -239 | -119 | -121 | -4,068 | 441 | -1,065 |
| Shares Outstanding | 1,392 | 1,381 | 1,370 | 1,358 | 1,341 | 1,324 | 1,341 | 1,407 | 1,509 | 1,518 |
| Earnings Per Share | 3.33 | 1.19 | 0.08 | 0.25 | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 | -0.70 |
| EPS Growth | 179.83% | 1387.5% | -68% | - | - | - | - | - | - | - |
| Operating Cash Flow | 1,836 | 310 | 1,426 | 1,182 | 691 | 1,269 | 1,110 | 1,280 | 1,008 | 325 |
| Capital Expenditures | -402 | -302 | -319 | -347 | -247 | -259 | -192 | -210 | -288 | -267 |
| Free Cash Flow | 1,434 | 8.00 | 1,107 | 835 | 444 | 1,010 | 918 | 1,070 | 720 | 58.00 |
| Cash & Equivalents | 217 | 146 | 188 | 196 | 319 | 587 | 217 | 207 | 267 | 213 |
| Total Debt | 10,008 | 7,056 | 5,616 | 5,484 | 5,677 | 4,244 | 4,240 | 4,256 | 4,261 | 5,438 |
| Net Cash / Debt | -9,791 | -6,910 | -5,428 | -5,288 | -5,358 | -3,657 | -4,023 | -4,049 | -3,994 | -5,225 |
| Assets | 30,565 | 20,999 | 19,042 | 18,096 | 18,133 | 17,024 | 16,571 | 17,154 | 21,290 | 22,128 |
| Liabilities | 16,688 | 12,273 | 12,030 | 11,363 | 11,813 | 10,567 | 10,032 | 10,284 | 9,937 | 10,832 |
| Book Value | 13,877 | 8,726 | 7,012 | 6,733 | 6,320 | 6,457 | 6,539 | 6,870 | 11,353 | 11,296 |
Company Profile
Company Details
| Full Name | Boston Scientific Corporation |
| Country | United States |
| Employees | 36,000 |
| CEO | Michael F. Mahoney |
Stock Information
| Ticker Symbol | BSX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Appliances & Equipment |
| Unique Identifier | NYSE: BSX |
| IPO Date | May 18, 1992 |
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.